MediWound (NASDAQ:MDWD – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, November 21st. Analysts expect MediWound to post earnings of ($0.45) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
MediWound Price Performance
Shares of MDWD stock opened at $8.33 on Friday. The stock has a market cap of $76.72 million, a P/E ratio of -3.43 and a beta of 1.03. MediWound has a one year low of $7.10 and a one year high of $14.58. The stock has a fifty day moving average price of $8.66 and a 200 day moving average price of $9.28.
Analyst Ratings Changes
MDWD has been the subject of a number of analyst reports. HC Wainwright lifted their price objective on MediWound from $23.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, September 21st. Oppenheimer cut their price objective on MediWound from $63.00 to $36.00 and set an “outperform” rating for the company in a report on Thursday, August 17th. Finally, StockNews.com cut MediWound from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.00.
Institutional Trading of MediWound
Hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in shares of MediWound in the first quarter valued at $1,998,000. Sphera Funds Management LTD. increased its position in MediWound by 47.4% in the first quarter. Sphera Funds Management LTD. now owns 111,127 shares of the biopharmaceutical company’s stock worth $1,480,000 after purchasing an additional 35,714 shares during the period. Wells Fargo & Company MN increased its position in MediWound by 16.0% in the second quarter. Wells Fargo & Company MN now owns 112,727 shares of the biopharmaceutical company’s stock worth $1,202,000 after purchasing an additional 15,535 shares during the period. Renaissance Technologies LLC increased its position in MediWound by 3.8% in the second quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock worth $875,000 after purchasing an additional 17,600 shares during the period. Finally, BlackRock Inc. increased its position in MediWound by 122.6% in the second quarter. BlackRock Inc. now owns 15,238 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 8,392 shares during the period. 22.32% of the stock is currently owned by institutional investors and hedge funds.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
- Five stocks we like better than MediWound
- Quiet Period Expirations Explained
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in Cannabis, Step by Step
- MarketBeat Week in Review – 11/13 – 11/17
- What is a Death Cross in Stocks?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.